Waldenstrom Macroglobulinemia Clinical Trial
Official title:
Phase II Study on the Combination of Ibrutinib and Venetoclax in Treatment naïve Patients With Waldenström Macroglobulinemia
Verified date | March 2024 |
Source | Dana-Farber Cancer Institute |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
This study evaluates the safety and efficacy of Ibrutinib combined with Venetoclax (IVEN) in the treatment of adults diagnosed with Waldenstrom's macroglobulinemia (WM) cancer with a specific MYD88 gene mutation. This research study involves an experimental drug combination of targeted therapies. The names of the study drugs involved in this study are: - Venetoclax - ibrutinib
Status | Active, not recruiting |
Enrollment | 45 |
Est. completion date | February 1, 2028 |
Est. primary completion date | June 6, 2022 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 18 Years and older |
Eligibility | Inclusion Criteria: - Participants must meet the following criteria on screening examination to be eligible to participate. Screening evaluations including consent, physical exam, and laboratory assessments will be done within 30 days prior to Cycle 1 Day 1. Bone marrow biopsy & aspirate, and CT C/A/P will be done within 90 days prior to Cycle 1 Day 1. - Clinicopathological diagnosis of Waldenström macroglobulinemia [28]. - Known tumor expression of mutated MYD88 performed by a CLIA certified laboratory. - Symptomatic disease meeting criteria for treatment using consensus panel criteria from the Second International Workshop on Waldenström macroglobulinemia [29]. - Participants with symptomatic hyperviscosity (e.g. nosebleeds, headaches, blurred vision) must undergo plasmapheresis prior to treatment initiation. - Age = 18 years - ECOG performance status =2 (see Appendix A) - Measurable disease, defined as presence of serum immunoglobin M (IgM) with a minimum IgM level of >2 times the upper limit of normal of each institution is required - At the time of screening, participants must have acceptable organ and marrow function as defined below: - Absolute neutrophil count =500/uL (no growth factor permitted) - Platelets =50,000/uL (no platelet transfusions permitted) - Hemoglobin = 7 g/dL (transfusions permitted) - Total bilirubin < 1.5 x institutional ULN - AST(SGOT)/ALT(SGPT) =2.5 × institutional ULN - Estimated GFR =30 mL/min - Females of childbearing potential (FCBP) must use one reliable form of contraception or have complete abstinence from heterosexual intercourse during the following time periods related to this study: 1) while participating in the study; and 2) for at least 90 days after discontinuation from the study. FCBP must be referred to a qualified provider of contraceptive methods if needed. FCBP must have a negative serum pregnancy test at screening. - Men must agree to use a latex condom during treatment and for up to 90 days after the last dose of ibrutinib or venetoclax during sexual contact with a FCBP - Ability to understand and the willingness to sign a written informed consent document. - Exclusion Criteria - Participants who exhibit any of the following conditions at screening will not be eligible for admission into the study: - Participants who have one or more prior systemic therapies for WM. - Participants who are receiving any other investigational agents. - Participants with known CNS lymphoma. - Participants with known history of Human Immunodeficiency Virus (HIV), chronic hepatitis B virus (HBV) or hepatitis C (HCV) requiring active treatment. Note: Participants with serologic evidence of prior vaccination to HBV (i.e., HBs Ag-, and anti-HBs+ and anti-HBC-) and positive anti-HBc from IVIG may participate. - Concurrent administration of medications or foods that are moderate or strong inhibitors or inducers of CYP3A within 7 days prior to first dose of study drug. - Participants with chronic liver disease and hepatic impairment meeting Child-Pugh class C (Appendix B). - Concurrent administration of warfarin. - Concurrent systemic immunosuppressant therapy within 21 days of the first dose of study drug. - Vaccinated with live, attenuated vaccines within 4 weeks of first dose of study drug. - Recent infection requiring systemic treatment that was completed = 14 days before the first dose of the study drug. - Known bleeding disorders (e.g., congenital von Willebrand's disease or hemophilia) - History of stroke or intracranial hemorrhage within 6 months prior to enrollment. - Major surgery within 4 weeks of first dose of study drug. - Malabsorption syndrome or other condition that precludes enteral route of administration. - Female participants who are pregnant, breastfeeding, or planning to become pregnant while enrolled in this study or within 90 days of last dose of study drug. - Male participants who plan to father a child while enrolled in this study or within 90 days after the last dose of study drug - Participants with known history of alcohol or drug abuse. - Participants with inability to swallow pills. - On any active therapy for other malignancies with the exception of topical therapies for basal cell or squamous cell cancers of the skin. - Uncontrolled intercurrent illness including, but not limited to, ongoing or active infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, or psychiatric illness/social situations that would limit compliance with study requirements. - Participants with a history of non-compliance to medical regimens. - Participants who are unwilling or unable to comply with the protocol. |
Country | Name | City | State |
---|---|---|---|
United States | Dana Farber Cancer Institute | Boston | Massachusetts |
United States | Massachusetts General Hospital | Boston | Massachusetts |
Lead Sponsor | Collaborator |
---|---|
Dana-Farber Cancer Institute | AbbVie, Pharmacyclics LLC. |
United States,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Number of Participants With Very Good Partial Response Within 24 Cycles of Therapy | Proportion of patients with VGPR to therapy within 24 cycles of therapy initiation. (VGPR is >90% reduction in serum IgM from baseline) | The primary objective of VGPR within 24 cycles of therapy was assessed starting at Cycle 3 Day 1 through the End of Treatment visit, range of 2 to 21 months after the initiation of therapy. | |
Secondary | Number of Participants With Complete Response (CR) After 6 Cycles | Proportion of patients with a complete response after 6 cycles of therapy. A complete response (CR) is defined as having resolution of WM related symptoms, normalization of serum IgM levels with complete disappearance of IgM paraprotein by immunofixation, and resolution of any adenopathy or splenomegaly. | 6 Cycles (28 day cycle) | |
Secondary | Number of Participants With Complete Response (CR) After 12 Cycles | Proportion of patients with a complete response after 12 cycles of therapy. A complete response (CR) is defined as having resolution of WM related symptoms, normalization of serum IgM levels with complete disappearance of IgM paraprotein by immunofixation, and resolution of any adenopathy or splenomegaly. | 12 Cycles (28 day cycle) | |
Secondary | Number of Participants With Complete Response (CR) After 24 Cycles | Proportion of patients with a complete response after 24 cycles of therapy. A complete response (CR) is defined as having resolution of WM related symptoms, normalization of serum IgM levels with complete disappearance of IgM paraprotein by immunofixation, and resolution of any adenopathy or splenomegaly. | Complete response to therapy was assessed starting at Cycle 3 Day 1 through the End of Treatment visit, range of 2 to 21 months after the initiation of therapy. | |
Secondary | Overall Response | Proportion of patients with minor response (MR) , partial response (PR), very good partial response (VGPR), or complete response (CR) to therapy. | 72 months | |
Secondary | Rate of VGPR at 30 Months | Proportion of patients with a VGPR at 30 months from beginning therapy. | 30 Months | |
Secondary | Median Time to Response | Time from treatment initiation until achievement of a minor response (reduction in serum IgM >25%) or better. | 24 months | |
Secondary | Median Time to Major Response | Time from treatment initiation until partial response or better (>50% reduction in serum IgM) | 24 months | |
Secondary | Progression Free Survival (PFS) at 24 Months | Time from initiation of therapy until disease progression (>25% increase in serum IgM and 500 mg/dL absolute increase). | 24 months | |
Secondary | Progression Free Survival (PFS) at 36 Months | Time from initiation of therapy until disease progression (>25% increase in serum IgM and 500 mg/dL absolute increase). | 36 Months | |
Secondary | Progression Free Survival (PFS) at 48 Months | Time from initiation of therapy until disease progression (>25% increase in serum IgM and 500 mg/dL absolute increase). | 48 Months | |
Secondary | Progression Free Survival (PFS) at 60 Months | Time from initiation of therapy until disease progression (>25% increase in serum IgM and 500 mg/dL absolute increase). | 60 Months | |
Secondary | Overall Survival | Time from initiation of therapy until death | 72 months | |
Secondary | Time to Next Treatment | Time from initiation of IVEN protocol therapy until initiation of new line of therapy. | 72 months | |
Secondary | Number of Participants With Treatment Related Adverse Events as Assessed (CTCAE) Version 5.0 | CTCAE version 5.0 | 6 Months |
Status | Clinical Trial | Phase | |
---|---|---|---|
Enrolling by invitation |
NCT01804686 -
A Long-term Extension Study of PCI-32765 (Ibrutinib)
|
Phase 3 | |
Completed |
NCT03630042 -
Investigating the Safety and Efficacy of Rituximab and Pembrolizumab in Relapsed/Refractory Waldenström's Macroglobulinaemia
|
Phase 2 | |
Completed |
NCT02916979 -
Myeloid-Derived Suppressor Cells and Checkpoint Immune Regulators' Expression in Allogeneic SCT Using FluBuATG
|
Phase 1 | |
Active, not recruiting |
NCT05024045 -
Study of Oral LOXO-338 in Patients With Advanced Blood Cancers
|
Phase 1 | |
Recruiting |
NCT05952037 -
Study to Evaluate the Efficacy and Safety of BGB-11417 in Participants With Waldenström's Macroglobulinemia
|
Phase 2 | |
Completed |
NCT04062448 -
A Study of Ibrutinib in Combination With Rituximab, in Japanese Participants With Waldenstrom's Macroglobulinemia (WM)
|
Phase 2 | |
Completed |
NCT01527045 -
Donor Atorvastatin Treatment in Preventing Severe Acute GVHD After Nonmyeloablative Peripheral Blood Stem Cell Transplant in Patients With Hematological Malignancies
|
Phase 2 | |
Recruiting |
NCT03679455 -
A Study of Obinutuzumab (RO5072759) Induction in Patients With Relapsed/ Refractory Waldenström Macroglobulinemia, OBI-1
|
Phase 2 | |
Not yet recruiting |
NCT05099471 -
Efficacy of Venetoclax in Combination With Rituximab in Waldenström's Macroglobulinemia
|
Phase 2 | |
Not yet recruiting |
NCT04830046 -
Covid-19 Vaccine Responsiveness in MM and Waldenstrom
|
||
Terminated |
NCT02109224 -
Ibrutinib in Treating Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma in Patients With HIV Infection
|
Phase 1 | |
Completed |
NCT01093586 -
Donor Umbilical Cord Blood Stem Cell Transplant in Treating Patients With Hematologic Malignancies
|
Phase 2 | |
Active, not recruiting |
NCT03620903 -
Efficacy of First Line B-RI for Treatment Naive Waldenström's Macroglobulinemia
|
Phase 2 | |
Not yet recruiting |
NCT04702932 -
Establishment of Genomic, Transcriptomic and Functional Characteristics of Tumor Cells in Hyperinflammatory Hemopathies
|
||
Active, not recruiting |
NCT03133221 -
1630GCC: Zydelig Maintenance in B-Cell Non-Hodgkin's Lymphoma After Autologous Stem Cell Transplantation
|
Phase 2 | |
Completed |
NCT00608361 -
Dasatinib in Treating Patients With Solid Tumors or Lymphomas That Are Metastatic or Cannot Be Removed By Surgery
|
Phase 1 | |
Completed |
NCT00777738 -
Efficacy of Bortezomib (Velcade(R)) in Patients With Advanced Waldenström Macroglobulinemia
|
Phase 2 | |
Completed |
NCT00438880 -
Agatolimod Sodium, Rituximab, and Yttrium Y 90 Ibritumomab Tiuxetan in Treating Patients With Recurrent or Refractory Non-Hodgkin Lymphoma
|
Phase 1/Phase 2 | |
Active, not recruiting |
NCT00075478 -
Total-Body Irradiation With or Without Fludarabine Phosphate Followed By Donor Stem Cell Transplant in Treating Patients With Hematologic Cancer
|
Phase 3 | |
Completed |
NCT01272817 -
Nonmyeloablative Allogeneic Transplant
|
N/A |